TNYA (Tenaya Therapeutics) FCF Yield %: -37.99 (As of Jul. 06, 2026)


TNYA Tenaya Therapeutics Inc TNYA
32 GF Score
Price $0.78
! 4 Warning Signs
View Full Analysis

What is Tenaya Therapeutics FCF Yield %?

Tenaya Therapeutics TNYA +6.47% 32 FCF Yield % is -37.99 as of Jul. 06, 2026. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Tenaya Therapeutics ranks worse than 79.99% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Tenaya Therapeutics's Trailing 12-Month Free Cash Flow is $-64.63 Mil, and Market Cap is $170.13 Mil. Therefore, Tenaya Therapeutics's FCF Yield % for today is -37.99%.

The historical rank and industry rank for Tenaya Therapeutics's FCF Yield % or its related term are showing as below:

TNYA' s FCF Yield % Range Over the Past 10 Years
Min: -44.33   Med: -40.86   Max: -29.8
Current: -37.99


During the past 7 years, the highest FCF Yield % of Tenaya Therapeutics was -29.80%. The lowest was -44.33%. And the median was -40.86%.

TNYA's FCF Yield % is ranked worse than
79.99% of 1409 companies
in the Biotechnology industry
Industry Median: -9.21 vs TNYA: -37.99

Tenaya Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -8,553.33%.


Tenaya Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Tenaya Therapeutics FCF Yield % Related Terms


Tenaya Therapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Tenaya Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenaya Therapeutics FCF Yield % Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial -10.98 -93.06 -46.66 -73.96 -44.66

Tenaya Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -101.35 -63.27 -23.56 -36.33 -51.23

TNYA vs MIST, NRXP, TLSA: FCF Yield % Comparison

For the Biotechnology subindustry, Tenaya Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's FCF Yield % falls into.


TNYA
32GF Score
Tenaya Therapeutics Inc TNYA
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tenaya Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Tenaya Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-68.882 / 154.22474
=-44.66%

Tenaya Therapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-19.245 * 4 / 150.2501076
=-51.23%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -37.99 mean?
Tenaya Therapeutics (TNYA) has a FCF Yield % of -37.99 as of Jul. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tenaya Therapeutics and its competitors. According to the industry distribution chart, Tenaya Therapeutics ranks #1127 out of 1409 companies in the Biotechnology industry, placing it in the top 80%.
Is Tenaya Therapeutics' FCF Yield % too high?
Tenaya Therapeutics' current FCF Yield % is -37.99. Based on the distribution chart, Tenaya Therapeutics ranks #1127 out of 1409 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' FCF Yield % compare to MIST and NRXP?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #1127 out of 1409 companies for FCF Yield %. This places Tenaya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current FCF Yield % is -37.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current FCF Yield % of -37.99. The current FCF Yield % is -37.99. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current FCF Yield % is -37.99 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenaya Therapeutics Business Description

Address 171 Oyster Point Boulevard, Suite 500, 5th Floor, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score

Get the complete analysis for TNYA

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.78
Price